Shenandoah Biotechnology, Inc., a worldwide supplier of high-quality recombinant proteins, is pleased to provide Cell Therapy Grade™(CTG™) recombinant Human Interleukin-15 (hIL-15).  Interleukin 15 is a widely expressed proinflammatory cytokine that is structurally and functionally related to interleukin 2 (IL-2). IL-15 signals through JAK kinases to activate STAT3, STAT5, and STAT6 transcription factors. IL-15 regulates the activation of T cells, neutrophils, and macrophages, and is a stimulatory cytokine promoting dendritic cell function. IL-15 expression is dysregulated in chronic inflammatory disorders, including rheumatoid arthritis, psoriasis, and pulmonary inflammatory diseases. IL-15 combined with the other common g chain cytokines ( IL-2, IL-7 and IL-21) is being used to promote favorable anti-tumoral phenotypes in adoptive cellular therapies i.e. CAR T cell.

Shenandoah Biotechnology’s CTG™ Recombinant Human IL-15 is manufactured to the highest quality standard within the industry.  Rigorous quality control procedures ensure lot-to-lot consistency providing reproducibility in downstream cell culture processes.  The release of CTG™ hIL-15 and future releases in the CTG™ product line from Shenandoah Biotechnology will enhance the development of cell-based therapies within the biopharmaceutical industry.